|
03 Feb 2020 |
United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint
|
|
02 Feb 2020 |
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
|
|
02 Feb 2020 |
Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
|
30 Jan 2020 |
F-star Therapeutics Announces FDA Acceptance of IND Application for FS120
|
|
28 Jan 2020 |
FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
|
|
28 Jan 2020 |
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept in Pre-Clinical Study
|
|
28 Jan 2020 |
Leronlimab Under Evaluation for Potential Treatment of Coronavirus
|
|
28 Jan 2020 |
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
|
|
28 Jan 2020 |
AbCellera Is Mobilizing a Response to the Novel Coronavirus Outbreak as Part of Its DARPA P3 Program
|
|
28 Jan 2020 |
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
|
|
28 Jan 2020 |
Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
|
|
27 Jan 2020 |
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
|
|
27 Jan 2020 |
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
|
|
27 Jan 2020 |
AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan
|
|
27 Jan 2020 |
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
|
|
25 Jan 2020 |
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
|
|
25 Jan 2020 |
Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress
|
|
24 Jan 2020 |
Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-Invasive Urothelial Cancer
|
|
23 Jan 2020 |
The European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Paediatric Patients With Moderate to Severe Plaque Psoriasis
|
|
23 Jan 2020 |
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
|
|
22 Jan 2020 |
Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus
|
|
22 Jan 2020 |
FDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
|
|
21 Jan 2020 |
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
|
|
21 Jan 2020 |
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
|
|
21 Jan 2020 |
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
|
